Active Pharmaceutical Ingredient (API) Market Expected to Surpass US $ 326.7 Billion by 2028, According to Coherent Market Insights

0


SEATTLE, December 9, 2021 / PRNewswire / – According to Coherent Market Insights, the Active Pharmaceutical Ingredient (API) Market is estimated at 206.0 billion US dollars in 2021 and should present a TCCA of 6.8% during the forecast period (2021-2028).

CMI logo

Key trends and analysis of Global Active Pharmaceutical Ingredient (API) Market:

The increase in funding initiatives is expected to drive the growth of the Active Pharmaceutical Ingredients (APIs) market. For example, in May 2020, the U.S. Department of Health and Human Services (HHS) announced it will provide funding of US $ 354 million to Phlow Corporation, a pharmaceutical company, under a four-year contract to produce the active pharmaceutical ingredient (API) needed for drugs to treat patients with COVID-19 and related diseases. Likewise, in April 2021, the Ministry of Chemicals and Fertilizers announced that the government of India will invest around $ 47 million to set up 16 factories to manufacture active pharmaceutical ingredients (API) in the country. Commercial production from these factories is expected to begin on April 1, 2023.

Request a copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/738

Key points of the market:

The global active pharmaceutical ingredients (APIs) market is expected to post a CAGR of 6.8% during the forecast period owing to the increasing expansion of facilities of major market players to develop APIs. For example, in February 2020, Sanofi, a pharmaceutical company has developed a new large European manufacturing and supply capacity for the production and marketing of active pharmaceutical ingredients (APIs). This project is to produce a separate company that combines the commercial and API development activities of Sanofi with six of its European API production sites such as Brindisi, Frankfurt Chemistry, Haverhill, St Aubin les Elbeuf, Ujpest and Vertolaye.

Among the type of product, the low-power API segment is expected to account for the largest market share in the world Active Pharmaceutical Ingredient (API) Market in 2021 due to the falling cost of producing bulk APIs, fewer technical hurdles for low power APIs, increased R&D spending by biopharmaceutical companies, and the growing number of development organizations and contract manufacturing (CDMO). The low power API product type includes APIs, which are effective at higher doses compared to high power APIs. These are traditional APIs, which are mainly used for the production of brand name drugs and generic drugs.

Among the molecular type, the small molecule segment is expected to account for the largest market share in the global active pharmaceutical ingredients (API) market in 2021, due to its property of high diffusion across biological barriers and fluids due to the small size molecules. For example, in April 2021, according to Nature Biomedical Engineering, chemotherapy, antibiotics, and steroids are examples of small molecule drugs (900 daltons) that are discovered, manufactured, and used as pharmaceuticals. Small molecule drugs, due to their small size, can diffuse rapidly through biological fluids, across many biological barriers, and across cell membranes.

Based on the formulation, the oral segment is expected to account for the largest market share in the global active pharmaceutical ingredients (API) market in 2021, owing to the increase in the pipeline of drugs, which constitute the oral ingredient, the increasing approval of new molecules with oral dosage forms, relatively easy to manufacture and chemical stability. For example, in july 2020, Glenmark Pharmaceuticals, a India– a based pharmaceutical company has started a post-market surveillance study (PMS) on FabiFlu, an antiviral drug to closely monitor the efficacy and safety of the drug in 1,000 patients who are prescribed with the oral antiviral, in as part of an open, multicenter, single study of the arm.

Based on a request, the cardiovascular disease segment is expected to account for the largest market share in the active pharmaceutical ingredients (API) market during the forecast period, owing to the high prevalence of cardiovascular disease. For example, in June 2021According to the World Health Organization (WHO), cardiovascular disease (CVD) was the leading cause of death worldwide. An estimated 17.9 million people died from cardiovascular disease in 2019, accounting for 32% of all deaths worldwide and 85% of deaths were due to heart attack and stroke.

Among the regions, North America is expected to hold a dominant position in the growth of the global active pharmaceutical ingredients (APIs) market during the forecast period. The growing epidemiology of cancer, along with the increasing incidence of other chronic diseases, is driving the R&D efforts and US FDA approvals, which are expected to drive the market growth. For example, in May 2020, the United States Food and Drug Administration (FDA) has approved aezolizumab (TECENTRIQ), manufactured by Genentech Inc., in North America. It is used for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).

Buy this premium report now @ https://www.coherentmarketinsights.com/insight/buy-now/738

Competitive landscape:

Major players operating in the global active pharmaceutical ingredients (API) market include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan NV, Amneal Pharmaceuticals LLC, Lonza Group, Lupine Limited, Fresenius Kabi, Hikma Pharmaceuticals, Cipla Limited, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, Aurobindo Pharma Limited, Apotex Inc, Taro Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Krka Pharmaceuticals, CordenPharma International, Evonik Industries AG and Biological E. Limit.

Market segmentation :

Global Active pharmaceutical ingredient Market (API), by product type:

  • Low power API

  • Highly powerful APIs

Global Active pharmaceutical ingredient Market (API), By Molecular Type:

  • Small molecules

  • Large Molecules

Global Active pharmaceutical ingredient Market (API), by formulation:

  • Oral

  • Topical

  • Injectable

  • Drops

Global Active pharmaceutical ingredient Market (API), By Application:

  • Diabetes

  • Oncology

  • Cardiovascular

  • SNC

  • Pain relievers

  • Ophthalmic

  • Respiratory

  • Dermatology

  • Others

Global Active Pharmaceutical Ingredient (API) Market, by region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Need more details? Please speak to analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/738

About Us:

Consistent market information is a global market intelligence and consulting organization that aims to help our plethora of clients achieve transformational growth by helping them make critical business decisions. We are based in India, having a global finance capital sales office in the United States and sales consultants in UK and Japan. Our clientele includes players from various industries in more than 57 countries around the world.

Contact us:

Mr. Shah
Senior Client Partner – Business Development
Consistent market information
Call:
we: + 1-206-701-6702
UK: + 44-020-8133-4027
Japan: + 81-050-5539-1737
India: + 91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow us: LinkedIn | Twitter

Cision

Cision

View original content: https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredient-api-market-to-surpass-us-326-7-billion-by-2028–says-coherent- market -information-301441004.html

SOURCE Consistent market insights



Share.

Comments are closed.